Objective To compare the clinical efficacy of high-dose tigecycline(TGC)and polymyxin B(PMB)in the treatment of pulmonary infection due to carbapenem-resistant organism(CRO).Methods Clinical data of pa-tients with CRO pulmonary infection and received PMB or high-dose TGC combined with other antimicrobial treat-ment regimens in Department of Critical Care Medicine of Xiangya Hospital,Central South University from January 2019 to March 2022 were analyzed retrospectively,including basic information,pathogen detection results,antimi-crobial use regimen,clinical efficacy,30-day mortality,bacterial clearance rate,etc.Results A total of 173 pa-tients were included in analysis,with 103 in the TGC group and 70 in the PMB group.Compared with TGC group,PMB group had a higher score of acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ)(25.0 vs 20.0,P＜0.001),but clinical efficacy rates were not statistically different(67.1％vs 52.4％,P=0.054).Stratified analysis revealed that when the APACHE Ⅱ score was ≥15 points,compared with TGC group(n=78),PMB group(n=66)had a higher APACHE Ⅱ score(27.0 vs 22.0,P=0.005)and a higher clinical efficacy rate(66.7％vs 47.4％,P=0.020).After adjusting confounding factors through logistic regression analysis,it was found that PMB treatment was a protective factor for clinical efficacy rate compared with TGC treatment.Conclusion For treating pulmonary infection caused by CRO in patients,PMB-based treatment regimen has a significant protec-tive effect on the clinical efficacy rate compared with the high-dose TGC-based treatment regimen.

Objective To compare the clinical efficacy of high-dose tigecycline(TGC)and polymyxin B(PMB)in the treatment of pulmonary infection due to carbapenem-resistant organism(CRO).Methods Clinical data of pa-tients with CRO pulmonary infection and received PMB or high-dose TGC combined with other antimicrobial treat-ment regimens in Department of Critical Care Medicine of Xiangya Hospital,Central South University from January 2019 to March 2022 were analyzed retrospectively,including basic information,pathogen detection results,antimi-crobial use regimen,clinical efficacy,30-day mortality,bacterial clearance rate,etc.Results A total of 173 pa-tients were included in analysis,with 103 in the TGC group and 70 in the PMB group.Compared with TGC group,PMB group had a higher score of acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ)(25.0 vs 20.0,P＜0.001),but clinical efficacy rates were not statistically different(67.1％vs 52.4％,P=0.054).Stratified analysis revealed that when the APACHE Ⅱ score was ≥15 points,compared with TGC group(n=78),PMB group(n=66)had a higher APACHE Ⅱ score(27.0 vs 22.0,P=0.005)and a higher clinical efficacy rate(66.7％vs 47.4％,P=0.020).After adjusting confounding factors through logistic regression analysis,it was found that PMB treatment was a protective factor for clinical efficacy rate compared with TGC treatment.Conclusion For treating pulmonary infection caused by CRO in patients,PMB-based treatment regimen has a significant protec-tive effect on the clinical efficacy rate compared with the high-dose TGC-based treatment regimen.

Objective To explore the effect of 3M skin protective film combined with colostomy powder on dermatitis caused by bowl movement incontinence . Methods Sixty-three patients with fecal incontinence were randomly divided into observation group (n =32) and control group (n=31). The control group received routine nursing and the observation group was treated with 3M skin protective film combined with Cambel colostomy powder. The two groups were compared in terms of incidence and severity of incontinent dermatitis. Result The duration of dermatitis in the observation group was significantly longer than that in the control group, while the incidence of incontinent dermatitis and severity were significantly lower than those in the control group (all P<0.01). Conclusion 3M skin protective film combined with Cambel colostomy powder can prevent incontinent dermatitis so as to relieve patients′pain. It is worthy of clinical popularization and application.

Objective To explicit the expression and role of miR-26a in gastric cancer tissues, thus to reveal molecular mechanism that miR-26a functions in gastric cancer cells. Methods The qRT-PCR was conducted for detect the ex-pression of miR-26a in 71 cases of gastric cancers. AGS cells were transfected with miR-26a mimics, then Western blot was performed to detect the expressions of MTDH protein. The proliferation ability of AGS cells evaluated by MTT assy. Results qRF-PCR showed that miR-26a was down-regulated 0.44 times in 71 cases of gastric cancer tissues. Western blot showed that the expressions of MTDH protein was inhibited by restored miR-26a or MTDH siRNA in AGS cells. Overexpression of miR-26a or MTDH siRNA inhibited the proliferation of AGS cells. Their OD values of transfected miR-26a mimics and MTDH siRNA were (0.158±0.006),(0.201±0.006) respectively, and their OD values of transfected control were (0.515±0.032),(0.479±0.028) respectively,there were statistically significance(P<0.05). Con-clusion miR-26a suppresses cell proliferation by targeting MTDH in gastric cancer.